C. tropicalis promotes CRC by down-regulating tumor cell-intrinsic PD-1 receptor via autophagy

Background: The programmed cell death 1 (PD-1) receptor is an immune checkpoint molecule that induces immune tolerance and mediates the immune escape of tumor cells. It is mainly expressed in immune cells such as T cells, B cells and monocytes. In recent years, studies have shown that tumor cell-intrinsic PD-1 plays different roles in the development of melanoma, Liver cancer and lung cancer. However, the expression and function of PD-1 in colon cancer cells has not been reported. Our previous studies have found that Candida tropicalis (C. tropicalis) can promote CRC tumor growth and chemotherapy resistance to oxaliplatin by regulating mismatch repair system. Whether C. tropicalis participates in the progression of CRC and immunotherapy resistance through regulating the tumor cell-intrinsic PD-1 remains to be further elucidated. Methods & Results: In this study, we first found that high concentrations of C. tropicalis promote tumor growth in cell cultures and xenografts. In addition, we proved that colon cancer cell lines express PD-1 receptors. Knockdown of PD-1 enhanced SW480 viability in-vitro, while overexpression of PD-1 diminished cell viability. Moreover, blocking antibody against PD-1 promotes tumor growth both in SW480 cells and mice CRC xenografts in an adaptive immune-independent manner. We also demonstrated that high concentrations of C. tropicalis can down-regulate tumor cell-intrinsic PD-1 expression in colon cancer cells. CRC cell growth induced by C. tropicalis is partially offset in the presence of PD-1 overexpression. This shows that C. tropicalis promotes CRC progression via controlling the expression of tumor cell-intrinsic PD-1. Mechanistically, we found that C. tropicalis modulates the expression of PD-1 via increasing the autophagy traffic in colon cancer cells. Combining autophagy inhibitor with C. tropicalis treatment partly blocked the CRC tumor growth and reversed the downregulation of PD-1. Conclusion: This study shows that PD-1 is a tumor suppressor in CRC. C. tropicalis can down-regulate tumor cell-intrinsic PD-1 expression via enhancing tumor cells autophagy levels to promote CRC progression. It may provide a new idea and mechanism for answering why the immune monoclonal antibody treatment is ineffective in cancer patients.

[1]  Ping Chen,et al.  C. tropicalis promotes chemotherapy resistance in colon cancer through increasing lactate production to regulate the mismatch repair system , 2021, International journal of biological sciences.

[2]  Fangfang Guo,et al.  F. nucleatum targets lncRNA ENO1-IT1 to promote glycolysis and oncogenesis in colorectal cancer , 2020, Gut.

[3]  T. Mariolis-Sapsakos,et al.  Intestinal Microbiota in Colorectal Cancer Surgery , 2020, Cancers.

[4]  Christopher R. Cabanski,et al.  Long non-coding RNA RAMS11 promotes metastatic colorectal cancer progression , 2020, Nature Communications.

[5]  G. Gao,et al.  Tumor cell-intrinsic PD-1 receptor is a tumor suppressor and mediates resistance to PD-1 blockade therapy , 2020, Proceedings of the National Academy of Sciences.

[6]  A. Need,et al.  Mutational signature in colorectal cancer caused by genotoxic pks+E. coli , 2020, Nature.

[7]  Jun Sun,et al.  Influence of the Gut Microbiome, Diet, and Environment on Risk of Colorectal Cancer. , 2020, Gastroenterology.

[8]  Z. Stadler,et al.  Immunotherapy in colorectal cancer: rationale, challenges and potential , 2019, Nature Reviews Gastroenterology & Hepatology.

[9]  S. Mazmanian,et al.  The Protective Role of Bacteroides fragilis in a Murine Model of Colitis-Associated Colorectal Cancer , 2018, mSphere.

[10]  M. Hung,et al.  The Adaptor Protein CARD9 Protects against Colon Cancer by Restricting Mycobiota‐Mediated Expansion of Myeloid‐Derived Suppressor Cells , 2018, Immunity.

[11]  Ti-Cheng Chang,et al.  SYK‐CARD9 Signaling Axis Promotes Gut Fungi‐Mediated Inflammasome Activation to Restrict Colitis and Colon Cancer , 2018, Immunity.

[12]  Ita Novita Sari,et al.  Toll-Like Receptor 2-Mediated Suppression of Colorectal Cancer Pathogenesis by Polysaccharide A From Bacteroides fragilis , 2018, Front. Microbiol..

[13]  B. Zhang,et al.  Programmed cell death‐1 (PD‐1) checkpoint blockade in combination with a mammalian target of rapamycin inhibitor restrains hepatocellular carcinoma growth induced by hepatoma cell–intrinsic PD‐1 , 2017, Hepatology.

[14]  A. Dicker,et al.  Blockade of Tumor-Expressed PD-1 promotes lung cancer growth , 2017, Oncoimmunology.

[15]  J. Wargo,et al.  Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy , 2017, Cell.

[16]  V. Boussiotis.  Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway. , 2016, The New England journal of medicine.

[17]  E. White,et al.  Recent insights into the function of autophagy in cancer , 2016, Genes & development.

[18]  Changying Jiang,et al.  Dectin-3 Deficiency Promotes Colitis Development due to Impaired Antifungal Innate Immune Responses in the Gut , 2016, PLoS pathogens.

[19]  R. Xavier,et al.  CARD9 impacts colitis by altering gut microbiota metabolism of tryptophan into aryl hydrocarbon receptor ligands , 2016, Nature Medicine.

[20]  Jedd D. Wolchok,et al.  PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations , 2016, Science Translational Medicine.

[21]  George F. Murphy,et al.  Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth , 2015, Cell.

[22]  Seamus J. Martin,et al.  Autophagy in malignant transformation and cancer progression , 2015, The EMBO journal.

[23]  M. J. B. Silva,et al.  The Multifaceted Role of Commensal Microbiota in Homeostasis and Gastrointestinal Diseases , 2015, Journal of immunology research.

[24]  F. Coppedè,et al.  Genetic and epigenetic biomarkers for diagnosis, prognosis and treatment of colorectal cancer. , 2014, World journal of gastroenterology.

[25]  David T. W. Jones,et al.  Signatures of mutational processes in human cancer , 2013, Nature.

[26]  L. Zitvogel,et al.  Targeting PD-1/PD-L1 interactions for cancer immunotherapy , 2012, Oncoimmunology.

[27]  E. White.  Deconvoluting the context-dependent role for autophagy in cancer , 2012, Nature Reviews Cancer.

[28]  Drew M. Pardoll,et al.  The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.

[29]  M. Diaz-Meco,et al.  p62 at the Crossroads of Autophagy, Apoptosis, and Cancer , 2009, Cell.

[30]  T. Okazaki,et al.  PD-1 and PD-1 ligands: from discovery to clinical application. , 2007, International immunology.

[31]  G. Freeman,et al.  PD-L2 is a second ligand for PD-1 and inhibits T cell activation , 2001, Nature Immunology.

[32]  G. Freeman,et al.  Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation , 2000, The Journal of experimental medicine.

[33]  L. Jeffrey Medeiros,et al.  Signaling pathway and dysregulation of PD1 and its ligands in lymphoid malignancies. , 2016, Biochimica et biophysica acta.